Hospital Pharmacy - April 2018 - 84

84

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

Hospital Pharmacy 53(2)
NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother.
2017;61(5):1-14.
Lin CW, Dutta S, Zhao W, Asatryan A, Campbell A, Liu
W.Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers [published online ahead of print July 7, 2017]. Eur J Drug Metab
Pharmacokinet. doi:10.1007/s13318-017-0428-8.
Lin CW, Dutta S, Ding B, et al. Pharmacokinetics, safety, and
tolerability of glecaprevir and pibrentasvir in healthy white,
Chinese, and Japanese adult subjects. J Clin Pharmacol.
2017;57(12):1616-1624.
American Association for the Study of Liver Diseases, Infectious
Diseases Society of America, and International Antiviral
Society. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org.
Updated September 21, 2017. Accessed October 16, 2017.
Foster GR, Gane E, Asatryan A, et al. ENDURANCE-3:
safety and efficacy of glecaprevir/pibrentasvir compared
to sofosbuvir plus daclatasvir in treatment-naïve HCV
genotype 3-infected patients without cirrhosis [abstract]. J
Hepatol. 2017;66(1)(suppl):S33.
Zeuzem S, Feld JJ, Wang S, et al. ENDURANCE-1: efficacy
and safety of 8- versus 12-week treatment with ABT-493/
ABT-530 in patients with chronic HCV genotype 1 infection
[abstract]. Hepatology. 2016;64(1)(suppl):133A.
Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir
and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology. 2017;66(2):389-397.
Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and
pibrentasvir yield high response rates in patients with HCV
genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263271.
Hassanein TI, Wyles DL, Wang S, et al. SURVEYOR-II,
part 4: glecaprevir/pibrentasvir demonstrates high SVR rates
in patients with HCV genotype 2, 4, 5, or 6 infection without
cirrhosis following an 8-week treatment duration [abstract].
Hepatology. 2016;64(6)(suppl):1128A.
Asselah T, Hezode C, Zodeikis N, et al. ENDURANCE-4:
efficacy and safety of ABT-493/ABT-530 treatment in
patients with chronic HCV genotype 4, 5, or 6 infection
[abstract]. Hepatology. 2016;64(1)(suppl):63A.
Cox EM. NDA approval letter: Mavyret (glecaprevir/pibrentasvir NDA 209394). Food and Drug Administration. https://

15.

16.

17.

18.

19.

20.

21.

22.

23.

www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/20
9394Orig1s000ltr.pdf. Published August 3, 2017. Accessed
September 5, 2017.
Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir
for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in
adults with compensated cirrhosis (EXPEDITION-1): a singlearm, open-label, multicentre phase 3 trial. Lancet Infect Dis.
2017;17(10):1062-1068.
Gane E, Poordad F, Wang S, et al. High efficacy of ABT493 and ABT-530 treatment in patients with HCV genotype
1 or 3 infection and compensated cirrhosis. Gastroenterology.
2016;151(4):651-659.e1.
Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, part 2:
glecaprevir and pibrentasvir for 12 or 16 weeks in patients
with chronic hepatitis C virus genotype 1 or 4 and prior
direct-acting antiviral treatment failure [abstract]. J Hepatol.
2017;66(suppl):S83.
Gane EJ, Lawitz E, Pugatch D, et al. EXPEDITION-IV: safety
and efficacy of GLE/PIB in adults with renal impairment and
chronic hepatitis C virus genotype 1-6 infection [abstract].
Hepatology. 2016;64(6)(suppl):1125A.
Reau N, Kwo PY, Rhee S, et al. MAGELLAN-2: safety and
efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
[abstract]. J Hepatol. 2017;66(1)(suppl):S90.
Rockstroh J, Lacombe K, Viani R, et al. Efficacy and
safety of glecaprevir/pibrentasvir in patients co-infected
with hepatitis C virus and human immunodeficiency virus1: the EXPEDITION-2 study [abstract]. J Int AIDS Soc.
2017;20(suppl 5):13.
Highleyman L. IAS 2017: glecaprevir/pibrentasvir effective
for people with HIV/HCV coinfection. HIVandHepatitis.
com. http://www.hivandhepatitis.com/hepatitis-c/hepatitis-ctopics/hcv-treatment/6095-ias-2017-glecaprevirpibrentasvireffective-for-people-with-hivhcv-coinfection. Published August
7, 2017. Accessed October 16, 2017.
Kosloski MP, Dutta S, Zhao W, et al. Lack of significant drugdrug interactions between direct acting antivirals glecaprevir
and pibrentasvir with calcium channel blockers (felodipine and
amlodipine) [abstract]. Clin Pharmacol Ther. 2017;101(suppl
1):S70.
Kosloski MP, Dutta S, Viani RM, et al. Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens
[abstract]. Top Antivir Med. 2017;25(suppl 1):168s.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209394Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209394Orig1s000ltr.pdf http://www.hcvguidelines.org http://www.hivandhepatitis.com/ http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/6095-ias-2017-glecaprevirpibrentasvir-%20effective-for-people-with-hivhcv-coinfection http://www.hivandhepatitis.com/ http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/6095-ias-2017-glecaprevirpibrentasvir-%20effective-for-people-with-hivhcv-coinfection http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/6095-ias-2017-glecaprevirpibrentasvir-%20effective-for-people-with-hivhcv-coinfection https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209394Orig1s000ltr.pdf

Table of Contents for the Digital Edition of Hospital Pharmacy - April 2018